Eventos adversos y problemas relacionados con Ustekinumab reportadas al Programa distrital de Farmacovigilancia en Bogotá D. C. 2014 a 2017

83 páginas : ilustraciones, gráficas ; Ustekinumab is a human monoclonal antibody that binds to the shared p40 subunit of interleukin (IL) -12 and IL-23, blocking the signaling of its cognate receptors. A moderate plaque was presented in the treatment of psoriasis, but it had recently been approved in adults with active psoriatic arthritis. Inhibitors of tumor necrosis factor (TNF) continue to be biological agents of the first line for the treatment of psoriatic arthritis, (McKeage, 2014) in many cases its administration causes adverse reactions that respond to an important public health problem, a negative impact on the health of the patients and an increase in the costs of health care, for this reason it is a question of carrying out a research work, in order to identify the adverse reactions generated by the use of this, and that have previously notified to the pharmacovigilance information program in the city of Bogotá, with the intention of identifying it. It will focus on this study. A detailed description Adverse reactions, identification strategies and prevention and adverse effects. even the most severe ones, such as anaphylaxis, (EUROPEAN MEDICINES AGENCY, 2017). Currently, stories are detected during preclinical and clinical trials, but they only become evident when the medication is something like a post-marketing surveillance, which security of its use. (Clape Laffita, Hodelín Tablada, Rodríguez Fernández, and Torres de la Rosa, 2000). ; Ustekinumab es un anticuerpo monoclonal humano que se une a la subunidad p40 compartida de interleucina (IL) -12 e IL-23, bloqueando la señalización de sus receptores afines. Se estableció en el tratamiento de la psoriasis en placa de moderada a grave, pero recientemente recibió aprobación en adultos con artritis psoriásica activa. Los inhibidores del factor de necrosis tumoral (TNF) siguen siendo agentes biológicos de primera línea para el tratamiento de la artritis psoriásica, (McKeage, 2014) en muchos casos su administración provoca reacciones adversas que ...